OncoMatch/Clinical Trials/NCT06704269
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Is NCT06704269 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies non-drug interventions for generalized myasthenia gravis.
This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage MGFA CLASS III, MGFA CLASS IVA (MGFA)
Excluded: Stage MGFA I, MGFA II, MGFA IVB, MGFA V
MGFA Class III-IVa (gMG) at screening; Exclusively ocular myasthenia gravis (MGFA I), mild symptoms (MGFA II), or severe bulbar disease or MG crisis, MGFA Class IVb or V at screening
Demographics
Prior therapy
Must have received: non-steroidal immunosuppressive drug
adequate treatment trials with at least two different non-steroidal immunosuppressive drugs given at adequate doses and duration of therapy
Cannot have received: anti-CD19 therapy
Prior treatment with anti-CD19 therapy
Cannot have received: adoptive T cell therapy
Prior treatment with ... adoptive T cell therapy
Cannot have received: gene therapy product (CAR-T cell therapy)
Prior treatment with ... any prior gene therapy product (e.g. CAR-T cell therapy)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Univ Cali Irvine ALS Neuromuscular · Orange, California
- Wake Forest Univ School of Medicine · Winston-Salem, North Carolina
- Houston Methodist Hospital · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06704269 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-CD19 therapy, adoptive T cell therapy, gene therapy product disqualifies patients from enrollment.
What disease stage is eligible?
Stage MGFA CLASS III or MGFA CLASS IVA is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify